{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:19:29Z","timestamp":1783480769045,"version":"3.55.0"},"reference-count":20,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) represent a keystone of cancer treatment, including non-small-cell lung cancer (NSCLC). Unfortunately, the efficacy of ICIs remains poor in patients with bone metastases from NSCLC. Recently, several case reports have suggested the clinical benefit of radiotherapy in advanced NSCLC patients. However, whether this positive effect is applicable during ICI treatment of NSCLC involving bones remains to be established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We retrospectively reviewed the records of patients with bone metastases who received ICIs as monotherapy (anti-PD1 or anti-programmed death-ligand 1) as well as in combination with platinum-based-chemotherapy (carboplatin or cisplatin). We next analyzed the presence or the absence of radiotherapy targeting bone metastases (RT) among these patients during immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 40 patients were included in this study; among them, 10 (25%) received palliative RT for symptomatic bone metastases during cancer immunotherapy treatment with ICIs (RT group); the remaining 30 (75%) patients did not receive bone irradiation (Non-RT group). We observed that the RT group had a significantly longer overall survival (OS) than the Non-RT group, with a median survival of 16\u2009months in the RT group versus 3\u2009months in the Non-RT group (log-rank test\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.048; hazard ratio (HR) for OS\u2009=\u20090.44; 95% confidence interval (CI): 0.18\u20131.00). Similar results were observed with respect to progression-free survival (PFS; log-rank test\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.016; HR for PFS\u2009=\u20090.34; 95% CI: 0.15\u20131.00).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our results suggest that radiotherapy to bone metastases may improve ICIs efficacy in patients with bone metastatic NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251332451","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T06:24:37Z","timestamp":1746426277000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of bone radiotherapy during immune checkpoint inhibitors treatment of non-small-cell lung cancer: a single-institution experience"],"prefix":"10.1177","volume":"17","author":[{"given":"Ivan","family":"Facilissimo","sequence":"first","affiliation":[{"name":"Division of Oncology, San Giovanni Bosco Hospital, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2477-5735","authenticated-orcid":false,"given":"Guido","family":"Natoli","sequence":"additional","affiliation":[{"name":"Division of Oncology, San Giovanni Bosco Hospital, Piazza del Donatore di Sangue 3, Torino 10154, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Gaspari","sequence":"additional","affiliation":[{"name":"Division of Oncology, San Giovanni Bosco Hospital, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Comandone","sequence":"additional","affiliation":[{"name":"Pharmacology, University of Turin, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Bongiovanni","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, San Giovanni Antica Sede Hospital, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Gollini","sequence":"additional","affiliation":[{"name":"Division of Radiology, San Giovanni Bosco Hospital, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Provenza","sequence":"additional","affiliation":[{"name":"Division of Pathology, San Giovanni Bosco Hospital, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Comandone","sequence":"additional","affiliation":[{"name":"Division of Oncology, San Giovanni Bosco Hospital, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.017"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.08.022"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0793-8"},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","unstructured":"Planchard D Popat S Kerr K et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up. Ann Oncol 2018; 29(Suppl. 4): iv192\u2013iv237 (updated version epublished https:\/\/www.esmo.org accessed 20 December 2023).","DOI":"10.1093\/annonc\/mdy275"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102352"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6631643"},{"key":"e_1_3_5_13_2","volume-title":"WHO classification of tumours of the lung, pleura, thymus and heart","author":"Travis WD","year":"2015","unstructured":"Travis WD, Brambilla E, Burke AP, et al. WHO classification of tumours of the lung, pleura, thymus and heart. Lyon, France: International Agency for Research on Cancer, 2015."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.09.009"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-1033"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2132"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1478"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318292c55a"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13539"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0105"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251332451","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251332451","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251332451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:32:03Z","timestamp":1777588323000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251332451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":20,"alternative-id":["10.1177\/17588359251332451"],"URL":"https:\/\/doi.org\/10.1177\/17588359251332451","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17588359251332451"}}